At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 61 enrolled
Drug / intervention
Levothyroxine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease
In Brief
A Phase 3 clinical trial evaluating Levothyroxine and Placebo for Graves' Disease. Completed, enrolled 61 participants across 1 site.
Detailed Summary
The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves'disease will prevent overt hypothyroidism (low thyroid hormone levels).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraves' Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedSep 2013
Primary CompletionApr 2017
TodayJul 2026
First PostedSep 25, 2013
Enrollment StartSep 1, 2013
Primary CompletionApr 1, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.8 years ago
Interventions
Levothyroxinedrug
Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
Placeboother
Placebo to start at 4 weeks after RAI